logo
Plus   Neg
Share
Email

Glencore Posts Loss In FY19; Sees 30% Cut In Absolute Scope 3 Emissions By 2035

Glencore Plc (GLCNF.PK,GLNCY.PK,GLEN.L) reported Tuesday that its fiscal 2019 net loss attributable to equity holders was $404 million, compared to last year's profit of $3.41 billion. Loss per share was $0.03, compared to profit of $0.24 a year ago.

The latest results included $2.8 billion of impairment charges.

Funds from operations or FFO declined 32 percent to $7.87 billion from $11.60 billion a year ago.

Adjusted EBITDA declined 26 percent to $11.60 billion. Adjusted EBIT dropped 55 percent to $4.15 billion.

Revenue declined to $215.11 billion from $220.52 billion last year.

Further, the company recommended 2020 base distribution of $0.20 per share, payable in two equal instalments.

Separately, the company updated its performance against position statement and disclosed a Scope 3 emissions projection for its business.

The company said it projects a c.30 percent reduction in Absolute Scope 3 emissions by 2035. This includes natural depletion of oil and coal resource base over time.

Further, the company said it is on track to achieve a near doubling its first GHG reduction target of reducing emissions intensity by at least 5 percent by 2020 compared to a 2016 base line. The company expects to achieve a c.10 percent reduction.

New longer-term Scope 1 and 2 targets that support the Paris goals will be announced during 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
RELATED NEWS
Follow RTT